Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.54 |
| ▸ | NOS3 | P29474 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21899450 | 0.79 | NOS2 (0.54) | NOS2NOS3LMNALIMK1CCR1 | |
| SCHEMBL2085241 | 0.78 | NOS2 (0.46) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL25346137 | 0.75 | CCR1 (0.32) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL8688305 | 0.75 | KDM4C (0.39) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL20767182 | 0.75 | CCR1 (0.35) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL12468608 | 0.75 | CCR1 (0.35) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL3716910 | 0.75 | CCR1 (0.35) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL20135919 | 0.75 | NOS2 (0.35) | NOS2NOS3LMNALIMK1CCR1 | |
| SCHEMBL28272737 | 0.72 | MAOA (0.37) | NOS2NOS3LIMK1CCR1CCR5 | |
| SCHEMBL1223407 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETADY OF HEALTH AND HUMAN SERVICES (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | DPYD, NTPCR, RRM2B | NOS2 1357/4885NOS3 1356/4885LMNA 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.